AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
46.68
+0.47 (1.02%)
At close: Jan 21, 2026, 4:00 PM EST
46.68
0.00 (0.00%)
After-hours: Jan 21, 2026, 4:11 PM EST
AnaptysBio Employees
AnaptysBio had 136 employees as of December 31, 2024. The number of employees increased by 19 or 16.24% compared to the previous year.
Employees
136
Change (1Y)
19
Growth (1Y)
16.24%
Revenue / Employee
$1,246,081
Profits / Employee
-$622,279
Market Cap
1.29B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 136 | 19 | 16.24% | 136 | 0 |
| Dec 31, 2023 | 117 | 21 | 21.88% | 117 | 0 |
| Dec 31, 2022 | 96 | -6 | -5.88% | 96 | 0 |
| Dec 31, 2021 | 102 | 8 | 8.51% | 102 | 0 |
| Dec 31, 2020 | 94 | 5 | 5.62% | 94 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 952 |
| Immatics | 682 |
| AbCellera Biologics | 596 |
| Xeris Biopharma Holdings | 394 |
| Relay Therapeutics | 261 |
| Day One Biopharmaceuticals | 181 |
| EyePoint | 165 |
| Capricor Therapeutics | 160 |
ANAB News
- 7 days ago - AnaptysBio, Inc. (ANAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 12 days ago - AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty - Reuters
- 13 days ago - Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary - GlobeNewsWire
- 15 days ago - Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PRNewsWire
- 2 months ago - Anaptys Announces Participation in December Investor Conferences - GlobeNewsWire
- 2 months ago - AnaptysBio shares tumble after legal fight with GSK over cancer drug license - Reuters
- 2 months ago - GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties - Benzinga